Targeting Innate Immunity with dsRNA‐Conjugated Mesoporous Silica Nanoparticles Promotes Antitumor Effects on Breast Cancer Cells | Zendy

Ultimo Amelia | Zendy; Giménez Cristina | Zendy; Bartovsky Pavel | Zendy; Aznar Elena | Zendy; Sancenón Félix | Zendy; Marcos M. Dolores | Zendy; Amorós Pedro | Zendy; Bernardo Ana R. | Zendy; MartínezMáñez Ramón | Zendy; JiménezLara Ana M. | Zendy; Murguía José R. | Zendy

Premium

Targeting Innate Immunity with dsRNA‐Conjugated Mesoporous Silica Nanoparticles Promotes Antitumor Effects on Breast Cancer Cells

Author(s) -

Ultimo Amelia,

Giménez Cristina,

Bartovsky Pavel,

Aznar Elena,

Sancenón Félix,

Marcos M. Dolores,

Amorós Pedro,

Bernardo Ana R.,

MartínezMáñez Ramón,

JiménezLara Ana M.,

Murguía José R.

Publication year - 2016

Publication title -

chemistry – a european journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.687

H-Index - 242

eISSN - 1521-3765

pISSN - 0947-6539

DOI - 10.1002/chem.201504629

Subject(s) - tlr3 , mesoporous silica , cancer cell , cytotoxic t cell , apoptosis , doxorubicin , innate immune system , chemistry , cytotoxicity , gene silencing , cancer research , mesoporous material , cancer , toll like receptor , receptor , biology , medicine , biochemistry , chemotherapy , in vitro , gene , catalysis

We describe herein a Toll‐like receptor 3 (TLR3) targeting delivery system based on mesoporous silica nanoparticles capped with the synthetic double stranded RNA polyinosinic–polycytidylic acid (poly(I:C)) for controlled cargo delivery in SK‐BR‐3 breast carcinoma cells. Our results show that poly(I:C)‐conjugated nanoparticles efficiently targeted breast cancer cells due to dsRNA–TLR3 interaction. Such interaction also triggered apoptotic pathways in SK‐BR‐3, significantly decreasing cells viability. Poly(I:C) cytotoxic effect in breast carcinoma cells was enhanced by loading nanoparticles′ mesopores with the anthracyclinic antibiotic doxorubicin, a commonly used chemotherapeutic agent.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research